Deciding Between Adjuvant Targeted Therapy and Immunotherapy in BRAF+ Melanoma

Source: OncLive, January 2021

When selecting between an adjuvant targeted therapy or immunotherapy for a patient with melanoma, it’s important to consider several factors, including the biologic behavior of the tumor, any comorbidities, toxicities, and patient concerns, according to Reinhard Dummer, MD.

Promising long-term data with targeted approaches have indicated that this class of agents improves progression-free survival (PFS) and distant metastases-free survival (MFS), according to Dummer.

However, this approach is not without toxicities. Several patients experience grade 3 adverse effects (AEs), such as pyrexia, which could lead to treatment discontinuation.

READ THE ORIGINAL FULL ARTICLE